New drug shows promise for rare skin cancers in early trial
NCT ID NCT05944562
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 31 times
Summary
This early-phase study tests a new drug called tulmimetostat (DZR123) in 24 adults with advanced mycosis fungoides or Sezary syndrome, rare types of skin lymphoma. Participants must have already tried at least one prior treatment. The main goals are to check the drug's safety and find the right dose, while also seeing if it helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.